Ostika Tablet 90 mg (Ticagrelor)

Adult dose

Do not use this medicine in combination with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer a loading dose of 180mg, followed by 90mg twice daily. Treatment for 12 months is recommended unless discontinuation is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who took 90mg of this medicine or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this medicine. Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuation of a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this medicine were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. For patients with acute coronary syndrome, refer to the dosage and administration for that condition. Data on the safety and efficacy of this medicine for treatment longer than 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer a loading dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. Administration of an initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. This medicine is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a glass of water, and drink it immediately. Rinse the glass with another half glass of water and drink it. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration. When switching from another antiplatelet agent to this medicine, begin this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and experience in patients with moderate hepatic impairment is limited.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age (see section ‘Other’).

This drug prevents platelet aggregation and thrombus formation. Use is not recommended in patients who have active bleeding or a history of intracranial hemorrhage. If surgery is planned, this medication should be discontinued at least 5 days prior, and any symptoms of bleeding should be reported to medical personnel immediately. Care should be taken when administering to patients at high risk of bleeding or those taking certain medications. Patients should be vigilant for symptoms of bleeding and respiratory distress while taking this medication. Patients with asthma or chronic obstructive pulmonary disease should be cautious as respiratory distress may worsen. This drug should not be administered in patients with severely impaired liver or kidney function or when combined with certain antibiotics or antifungals. Women who are pregnant or breastfeeding should avoid becoming pregnant during treatment with this drug and should consult their doctor about breastfeeding. Elderly patients or those with renal impairment may have increased drug concentrations and regular monitoring of renal function is necessary. This drug has not been established for safety and efficacy in children. In case of overdose, the risk of bleeding increases, and immediate medical attention should be sought. Caution should be exercised while driving or operating machinery as dizziness or confusion may occur. This medication can interact with various other drugs, so it is essential to inform medical personnel of any other medications being taken.

Hemorrhage, intracranial hemorrhage, ocular hemorrhage, ear hemorrhage, hypotension, respiratory distress, respiratory tract hemorrhage, gastrointestinal hemorrhage, diarrhea, nausea, dyspepsia, constipation, retroperitoneal hemorrhage, subcutaneous or skin hemorrhage, rash, itching, muscular hemorrhage, urinary tract hemorrhage, reproductive tract hemorrhage, confusion, dizziness, syncope, headache, vertigo, thrombotic thrombocytopenic purpura, bradyarrhythmia, heart block, angioedema, central sleep apnea including Cheyne-Stokes respiration, hyperuricemia, gout

Store this medication in a tightly sealed container to prevent exposure to air or moisture. It is best to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance

Yellow, double convex, round film-coated tablet

Package unit

56 tablets (14 tablets PTP x 4)